NeoStems Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014 - WLTZ 38 | Columbus Georgia Regional News & Community

NeoStems Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014

Posted: Updated:

NEW YORK, July 08, 2014 (GLOBE NEWSWIRE via COMTEX) — NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that two of its leading cancer immunotherapy experts, Dr. Andrew Pecora, Chief Visionary Officer, NeoStem; and Dr. Robert O. Dillman, Vice President, Oncology of the Company’s wholly-owned subsidiary, NeoStem Oncology LLC., will give presentations at the sub-conferences of the Novel Cancer Therapeutics Summit in Boston, Massachusetts on Monday, July 7.

Dr. Pecora will speak about highlights of NeoStem’s Targeted Immunotherapy Program that focuses on patient-specific immunotherapies for the treatment of late stage cancers, including NeoStem’s expected launch later this year of a pivotal Phase 3 trial for Melapuldencel-T, its lead product candidate. Dr. Dillman will speak about whether the best source of tumor-associated antigens may be autologous tumor cells that self-renew in tissue culture.

3 Annual Oncology Partnering and Deal Making :

Date and Time: Monday, July 7, 2014, 5:05 PM EDT

Venue: Hyatt Regency, Boston, MA

• Website: https://www.gtcbio.com

Presenter: Dr. Andrew Pecora, Chief Visionary Officer, NeoStem

Topic: Targeting Cancer Initiating Cells With a Novel Immunotherapy

5 Annual Cancer Targets and Therapeutics :

Date and Time: Monday, July 7, 2014, 2:30 PM EDT

Venue: Hyatt Regency, Boston, MA

Website: https://www.gtcbio.com

Presenter: Dr. Robert O. Dillman, Vice President, Oncology, NeoStem Oncology

Topic: Tumor Stem Cell Antigen-based Patient-Specific Therapeutic Vaccines in Metastatic Melanoma


About NeoStem, Inc. :

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com


About Melapuldencel-T :

NeoStem expects to initiate a pivotal Phase 3 trial for Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. The goal of the therapy is to eliminate or neutralize the tumor cells that are responsible for recurrence after medically induced tumor regression after a patient has already had undergone other treatments which may have reduced tumor size, but failed to entirely eliminate the cancer. Melapuldencel-T has been the subject of compelling trial results for the treatment of metastatic melanoma. As a result, Melapuldencel-T has been approved to enter a Phase 3 clinical trial with Special Protocol Assessment (SPA) and received Fast Track designation for metastatic melanoma, as well as Orphan Drug designation.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Targeted Immunotherapy Program (including whether or not Melapuldencel-T will successfully be developed to treat metastatic melanoma or any other cancer indications), CD34 Cell Program, T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, the Company’s Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Media Contact
Company Name: PublicWire
Contact Person: Dave Donlin
Email: Send Email
Phone: 4074906635
Address:5850 TG Lee Blvd, Suite 300
City: Orlando
State: FL
Country: United States
Website: http://publicwire.com

Source: www.abnewswire.com

ReleaseID: 13429

Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WLTZ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.